Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer

Localized prostate cancer is curable, but metastatic castration sensitive prostate cancer has a low 5-year survival rate, while broad treatment options are lacking. Here we present an mCSPC patient under remission receiving individualized neoantigen-derived peptide vaccination as recurrence prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales: Zelba, Henning, Rabsteyn, Armin, Bartsch, Oliver, Kyzirakos, Christina, Kayser, Simone, Seibold, Marcel, Harter, Johannes, Latzer, Pauline, Hadaschik, Dirk, Battke, Florian, Golf, Alexander, Rettig, Matthew B., Biskup, Saskia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619716/
https://www.ncbi.nlm.nih.gov/pubmed/37920460
http://dx.doi.org/10.3389/fimmu.2023.1271449

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619716/
https://www.ncbi.nlm.nih.gov/pubmed/37920460
http://dx.doi.org/10.3389/fimmu.2023.1271449

Ejemplares similares